Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy and Autologous Stem Cell Transplant in Lymphoma
NCT00004171Phase 2Completed
- Sponsor
- Northwestern University
- Start
- Oct 1999
- Primary completion
- Jun 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of busulfan and cyclophosphamide in Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), sponsored by Northwestern University. Primary endpoints: Toxicity at 1 year and Response Rate at 1 year. Started Oct 1999; status: completed.
02
Drugs
busulfancyclophosphamide
03
Conditions
Hodgkin lymphoma (HL)non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00004171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004171.